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OPEN
ORIGINAL ARTICLE
Evidence for metabolic endotoxemia in obese and diabetic
Gambian women
S Hawkesworth1, SE Moore1,2, AJC Fulford1,2, GR Barclay3, AA Darboe2, H Mark2, OA Nyan4 and AM Prentice1,2
OBJECTIVE: Emerging evidence from animal models suggests that translocation of bacterial debris across a leaky gut may trigger
low-grade inﬂammation, which in turn drives insulin resistance. The current study set out to investigate this phenomenon, termed
‘metabolic endotoxemia’, in Gambian women.
METHODS: In a cross-sectional study, we recruited 93 age-matched middle-aged urban Gambian women into three groups: lean
(body mass index (BMI): 18.5–22.9 kgm 2), obese non-diabetic (BMI: X30.0 kgm 2) and obese diabetic (BMI: X30.0 kgm 2 and
attending a diabetic clinic). We measured serum bacterial lipopolysaccharide (LPS) and endotoxin-core IgM and IgG antibodies
(EndoCAb) as measures of endotoxin exposure and interleukin-6 (IL-6) as a marker of inﬂammation.
RESULTS: Inﬂammation (IL-6) was independently and positively associated with both obesity and diabetes (F¼ 12.7, Po0.001). LPS
levels were highest in the obese-diabetic group compared with the other two groups (F¼ 4.4, Po0.02). IgM EndoCAb (but not total
IgM) was highly signiﬁcantly reduced in the obese (55% of lean value) and obese diabetic women (30% of lean; F¼ 21.7, Po0.0001
for trend) compared with lean women.
CONCLUSION: These data support the hypothesis that gut-derived inﬂammatory products are associated with obesity and
diabetes. Conﬁrmation of these ﬁndings and elucidation of the role of the microbiota, gut damage and the pathways for
translocation of bacterial debris, could open new avenues for prevention and treatment of type 2 diabetes.
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INTRODUCTION
Although obesity is the leading risk factor for metabolic syndrome,
insulin resistance and type 2 diabetes, not all obese individuals
go on to develop disease.1 Type 2 diabetes is a heterogeneous
condition with aetiologies reﬂecting a complex interaction
between genes and environment, including diet, physical
activity and factors operating in early life. Among these
exposures, low-grade inﬂammation (assessed by a range of
markers including C-reactive protein, sialic acid, tumour necrosis
factor (TNF) and interleukin-6 (IL-6)) has emerged as a consistent
correlate of metabolic syndrome2–4 and a strong predictor of
progression to incident type 2 diabetes among at-risk
individuals.5,6 Macrophage inﬁltration of adipose tissue, driven
by adipocyte-secreted macrophage chemotractant protein-1, has
hitherto been considered the most likely source of such
inﬂammation and could explain the correlations with adipose
tissue mass.7 However, recent research suggests an alternate
or additional explanation by which bacterial products are
translocated across the gut, either in association with a high-fat
diet or due to gut damage, and thereby drive the inﬂammation,
so-called ‘metabolic endotoxemia’ (ME).8–10
Animal and human data have suggested that the composition
of the gut microﬂora may be an important mediator of the
risk of obesity and diabetes.10,11 Germ-free mice are protected
against the metabolic complications of exposure to a high-fat/
high-reﬁned sugar ‘Western’ diet12 and the transplantation of gut
microbiota from obese animals results in adiposity in those who
are born germ-free.13 One suggested mechanism is through a
more efﬁcient energy harvest.14 Additional evidence suggests
that the microbiota can inﬂuence metabolic disease through a
separate mechanism. Bacterial lipopolysaccharide (LPS, also
termed endotoxin) is released from dead Gram-negative bacteria
in the gut and under conditions of gut damage can translocate
into the circulation (as can whole bacteria) where it triggers
an inﬂammatory response.15 Using mouse models, Cani and
colleagues have demonstrated that exposure to a high-fat diet
increases systemic endotoxin concentration, a phenomenon they
termed ‘ME’ in recognition of the fact that levels are much lower
than those observed in septic shock.9 In addition, mice infused
with similarly low levels of LPS demonstrate raised glucose
mimicking the levels observed for mice fed a high-fat diet.9
Few studies have investigated the association between
endotoxemia and obesity in humans. A study in Saudi Arabian
patients reported a positive association between endotoxin levels
and various components of the metabolic syndrome,16 whereas
another study in healthy French men reported a positive
association between energy intake and endotoxemia.17
The inner-core of LPS molecules is relatively conserved across
species and antibodies to this are therefore the most
cross-reactive.18 Anti-endotoxin core antibodies (EndoCAb)19
may provide information on longer-term endotoxin exposure
and have not yet been studied in the context of obesity
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and diabetes. Here we present data on the cross-sectional
association between diabetes and endotoxemia in urban-
dwelling lean, obese and obese diabetic Gambian women.
SUBJECTS AND METHODS
Three groups of women were recruited into the study from the urban
Bakau district of the Gambia, West Africa. We selected a lean (body mass
index (BMI): 18.5–22.9 kgm 2) and obese (BMI 430 kgm 2) group from
the general population using convenience sampling by screening house-
holds in the area and matching recruited women for age. A third group of
obese women with diagnosed type 2 diabetes mellitus were recruited from
the diabetic clinic at the Royal Victoria Teaching Hospital in the Gambian
capital of Banjul. The study protocol was approved by the Scientiﬁc
Coordinating Committee of Medical Research Council (MRC) Unit, the
Gambia, and ethics permission was granted by the joint Gambian
Government/MRC Ethics Committee. Full informed consent was obtained
from each participant before enrolment into the study.
Participants were invited to attend a study morning at MRC Fajara in a
fasted state. Weight was measured to the nearest 0.1 kg using daily
calibrated, digital scales (Tanita Corporation, Tokyo, Japan). Height was
measured using a daily calibrated stadiometer (Leicester height measure,
Seca 214, Birmingham, UK) to the nearest 0.1 cm and BMI was deﬁned as
weight(kg)/height(m).2 Body composition was further assessed by
bioelectrical impedance analysis using the Tanita BC-418MA (Tanita
Corporation) segmental analyser. Blood pressure was measured in
triplicate using the automated Omron 705IT device (Omron, Kyoto,
Japan) and following the manufacturer’s instructions. Stool and fasted
blood samples were collected, processed and frozen at  80 1C for analysis
at a later date. Women were also interviewed during the study visit and
data were recorded on their level of education and various assets owned
by their household.
Insulin was measured using the AxSYM Microparticle Enzyme Immu-
noassay (Abbott Laboratories, North Chicago, IL, USA) with a detection
limit of 1.0 mU insulin per ml. Glucose was measured on the VITROS 5600
Integrated System (Ortho-Clinical Diagnostics, Rochester, NY, USA) using
the slide method with a detection range of 1.11–34.69mmol l 1. Plasma
IL-6 was measured using the eBioscience IL-6 high-sensitivity ELISA with a
detection limit of 0.03 pgml 1 (Bender MedSystems, Vienna, Austria: intra-
assay CV: 4.9%). Faecal calprotectin was measured using the CALPRO
Calprotectin ELISA Test (ALP) with a detection limit of 6.25 ngml 1 (Fireﬂy
Scientiﬁc, Manchester, UK: intra-assay CV: 1.9%). Calprotectin was assayed
because faecal levels have been shown to correlate with the number of
polymorphonuclear granulocytes entering the gut lumen.20 Serum
endotoxin concentrations were measured using the Endpoint
Chromogenic Limulus Amebocyte Lysate Test for Gram-negative
bacterial endotoxin (LAL QCL-1000, Basal, Switzerland) with a detection
limit of 0.1 EUml 1. Samples were carefully processed for this assay using
endotoxin-free consumables. Total IgM was measured using an ELISA test
kit (Immunology Consultants Laboratory Inc., Portland, OR, USA).
Finally, endotoxin-core IgM and IgG antibodies (EndoCAb) were measured
by ELISA as described elsewhere.21,22 In brief, polystyrene microplates were
pre-coated with an equimolar mixture of incomplete-core rough mutant
endotoxins from each of four species of Gram-negative bacteria, complexed
with polymyxin B. An eight-point standard curve was constructed using
doubling dilutions of a pooled serum calibrated in EndoCAb median units
and was used on every plate. Test samples were diluted 1:200 with dilution
buffer and 100ml of each sample added in duplicate to the plate and
incubated for 60min at 37 1C. After washing four times with wash buffer,
100ml of a diluted alkaline phophatase-conjugated goat anti-human IgG or
IgM (Ig heavy-chain speciﬁc) antibody was added to each well and the plate
was incubated for a further 60min at 37 1C. The washing step was then
repeated four times and 100ml of the substrate solution (1mgml 1
disodium p-nitrophenylphosphate dissolved in 1M diethanolamine buffer)
was added to the plate wells. The plate was incubated in the dark for 35min
and the reaction was stopped with 500ml per well of 2 M sodium hydroxide
and read at 405nm. Repeat blood samples were collected on participants in
the lean and obese non-diabetic categories approximately 2 weeks after the
initial study visit in order to assess the reliability of the endotoxin and
endotoxin core antibody measurements.
Statistical analysis
Data were analysed using STATA 11 (Stata Corporation, College Station, TX,
USA). All biochemistry variables had right-skewed distributions and
residuals that were not normally distributed and were therefore
log-transformed for the analysis. Geometric means (95% conﬁdence
intervals) have been presented for the descriptive statistics of
these variables. Impaired fasting glucose was deﬁned as fasting glucose
X6.1–6.9mmol l 1, whereas diabetes was deﬁned as fasting glucose
X7.0mmol l 1 in accordance with WHO recommendations.23 Insulin
sensitivity was assessed by the QUICKI index (calculated as
1/(insulin(log)þglucose(log))) as several insulin values were below 20 pM,
the lower limit for which the Homeostasis Model Assessment was
validated.24 The EndoCAb values for IgG and IgM in the obese and
obese diabetic groups were calculated as a percentage of the mean value
for lean subjects. Thus, the lean group acted as a healthy control group
and the values for the other two groups were normalised with respect to
these controls; all EndoCAb values are expressed as percentage median
units (PMUs) where the mean for lean individuals is 100 PMU or 100%.
Descriptive statistics have been presented for the study participants
divided into the three recruitment groups: lean, obese, obese diabetic.
Analysis of variance was used to assess the difference in markers of
endotoxin and inﬂammation across the exposure groups. The association
between obesity and diabetes status and the markers of endotoxin and
inﬂammation was further assessed by using linear regression models ﬁrst
ﬁtting obesity (yes/no) as the explanatory variable and then ﬁtting both
obesity and diabetes as binary variables to assess any independent effect.
RESULTS
In total, 93 women were recruited; mean BMI for the lean group
was 20.8 kgm 2, for the obese group it was 34.3 kgm 2 and for
the obese diabetic group it was 33.3 kgm 2 (Table 1). Total and
trunkal fat masses were over 2.5-fold higher in the obese and
obese diabetic groups (total fat: 14.2, 39.5 and 37.8 kg; trunkal fat:
6.3, 20.0 and 19.1 kg). The majority of women (55%) had been
born in the urban region and the median amount of time spent
living there for individuals who had been born elsewhere was 25
years. All women in the obese diabetic group were receiving
medication to treat their condition. There was a marginal
difference in age between the three groups (analysis of variance,
F: 2.89; P-value: 0.06, df: 2,88), with women in the lean group on
average 3.6 years younger than women in the diabetic group. As
would be expected, diabetes prevalence (deﬁned as fasting
glucose above 7.0mmol l 1) was very different between the three
groups with no women in the lean group, one woman in the
obese non-diabetic group and 70% of women in the diabetic
group. For the nine individuals in the diabetic group who did not
have frank diabetes, their mean fasting glucose was still elevated
at 5.9mmol l 1 (s.d. 0.7). Some of the markers of socioeconomic
status were different between the groups with a much higher
proportion of women in both obese groups having completed at
least primary school education compared with lean participants.
Women in both obese categories also reported owning a larger
number of assets and having greater access to a ﬂush toilet
compared with women in the lean category.
Mean endotoxin detected in plasma for the entire sample was
4.25 EUml 1 (95% conﬁdence interval (CI): 3.65, 4.96). Repeat
samples were conducted on 48 individuals and the correlation
between the ﬁrst and second measurements was poor at
0.2. Mean anti-endotoxin IgG antibody for the entire sample was
109.6 PMU (95% CI: 94.53, 127.0) and the correlation between
repeat samples was 0.54. Mean anti-endotoxin IgM antibody for
the entire sample was 55.45 PMU (95% CI: 46.54, 66.07) and the
correlation between repeat samples was 0.82. The analysis
presented focuses on samples obtained from the ﬁrst study visit.
Stool samples were more difﬁcult to obtain than blood samples
due to reluctance by some participants and a total of 72 samples
were collected for the assessment of faecal calprotectin,
representing 77% of participants. Mean calprotectin was
45.73mg kg 1 (95% CI: 34.42, 60.76). Mean IL-6 for the entire
sample was 1.11 pgml 1 (95% CI: 0.92, 1.33).
Endotoxin levels were higher in the obese diabetic group
compared with both the lean and obese non-diabetic groups
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(Table 2), and, as expected, IL-6 levels were raised by obesity and
highest in the diabetic group. Anti-endotoxin IgG antibodies were
not different between the three groups, and there was no
difference in faecal calprotectin. Anti-endotoxin IgM antibodies
showed a very strong reverse association; both the obese non-
diabetic and obese diabetic groups had much lower levels than
the lean comparison group (F-ratio for trend¼ 21.73, Po0.0001).
In contrast, there was no difference in total IgM between the three
groups. Applying a Bonferroni correction (a¼ 0.01) to account for
multiple comparisons between groups still reveals a difference in
anti-endotoxin IgM and IL-6 levels between the three groups.
Simple linear regression analysis for all groups combined
showed a positive association between log fasting glucose and
log endotoxin levels (b: 0.24 EUml 1, 95% CI: 0.09, 0.38; P: 0.001)
but not between log fasting insulin and log endotoxin
(b: 0.20 EUml 1, 95% CI:  0.12, 0.51; P: 0.22). There was a
negative association between log fasting glucose and log anti-
endotoxin IgM antibodies (b:  0.16 PMU, 95% CI:  0.25,  0.07;
P: o0.001) and between log fasting insulin and anti-endotoxin
IgM (b:  0.24 PMU, 95% CI:  0.43,  0.06; P: 0.01). There was a
positive association between QUCKI index and log anti-endotoxin
IgM antibodies (b: 0.03 PMU, 95% CI: 0.01, 0.05; P: 0.01) but no
association with either endotoxin or anti-endotoxin IgG antibodies
(data not shown). There was also no association between anti-
endotoxin IgG antibodies and either glucose or insulin (data not
shown). There was a negative association between whole-body
fat mass and log anti-endotoxin IgM antibodies (b:  5.86 PMU,
95% CI:  9.29,  2.44; P: 0.001) but no association between
Table 1. Descriptive statistics of the study sample by BMI/diabetic group
Variable Mean (s.d.) or percentagea
Lean (n: 31) Obese (n: 33) Diabetic (n: 29)
Age (year) 41.5 (6.2) 43.4 (5.4) 45.1 (5.2)
Born in urban region (%) 67.7 57.6 51.7
Education (%)b 9.1 (n¼ 22) 38.5 (n¼ 26) 31.3 (n¼ 29)
Water within the home (%)c 63.3 71.9 75.0
Flush toilet (%)d 22.6 51.5 58.6
Assets ownede 4.2 (2.3) 5.8 (1.9) 6.7 (1.9)
Height (m) 1.6 (0.1) 1.6 (0.1) 1.6 (0.1)
Weight (kg) 55.0 (5.3) 90.2 (13.2) 87.2 (16.9)
BMI (kgm 2) 20.8 (1.8) 34.3 (4.5) 33.3 (5.7)
Fat mass (kg)f 14.2 (4.0) 39.5 (8.8) 37.8 (11.3)
Trunk fat mass (kg)f 6.3 (2.5) 20.0 (4.6) 19.1 (5.3)
Systolic BP (mmHg) 114.0 (14.1) 126.6 (19.7) 125.3 (17.1)
Diastolic BP (mmHg) 73.3 (8.8) 84.0 (12.3) 84.2 (9.3)
Hypertensive (%)g 6.7 26.7 13.8
Fasted glucose (mmol l 1) 5.00 (4.84, 5.17) 5.51 (5.23, 5.80) 9.19 (7.75, 10.89)
Fasted insulin (pgml 1) 4.31 (3.28, 5.65) 11.08 (9.08, 13.52) 12.11 (9.71, 15.09)
QUICKI indexh 0.35 (0.08) 0.25 (0.04) 0.22 (0.03)
Impaired fasting glucose (%)i 3.5 12.5 82.1
Diabetes (%)j 0 3.1 67.9
Abbreviations: BMI, body mass index; BP, blood pressure, CI, confidence interval. aGeometric means (95% CI) have been presented for skewed variables.
bProportion of women who have completed at least primary school compared with those with no formal schooling or only an Arabic school education.
cProportion of women who have a water source within their compound rather than using a public tap. dProportion of women who have a flush toilet
compared with a pit latrine. eTotal number of assets owned by the household calculated from yes/no answers to the following: electricity, television,
motorcycle, radio, bicycle, car, fridge, telephone, land, goats and chickens. fFat mass measured using the Tanita BC-418MA bioelectrical impedance analyser.
gHypertension defined as systolic BP4140mmHg. hInsulin sensitivity assessed by the QUCKI index calculated as QUICKI¼ 1/(log(Insulin)þ log(glucose)) used
as an estimate of insulin sensitivity. iImpaired fasting glucose defined as fasting glucoseX6.1mmol l 1. jDiabetes defined as fasting glucose X7.0mmol l 1.
Table 2. Distribution of inflammatory and endotoxin measurements by BMI/diabetic group
Variable Geometric mean (95% CI) or percentage ANOVA/logistic regressiona
Lean (n: 31) Obese (n: 33) Diabetic (n: 29)
Endotoxin (EU/ml) 3.89 (3.20, 4.73) 3.86 (3.30, 4.52) 5.19 (3.43, 7.87) F: 4.16 P: 0.02
EndoCAb-IgG (PMU)b 100.0 (71.71, 139.41) 121.22 (95.10, 254.50) 108.14 (88.72, 131.80) F: 0.57 P: 0.57
EndoCAb-IgM (PMU)b 100.00 (80.46, 124.29) 55.23 (41.51, 73.49) 30.26 (23.26, 39.37) F: 21.73 P: o0.001
Total IgM (mgdl 1) 65.79 (42.87, 100.97) 70.01 (48.41, 101.26) 69.79 (43.55, 111.85) F: 0.03 P: 0.97
Interleukin-6 (pgml 1) 0.60 (0.41, 0.88) 1.23 (0.97, 1.55) 1.92 (1.57, 2.35) F: 12.68 P: o0.001
Faecal calprotectin (mgkg 1) 39.38 (24.04, 64.51) 40.26 (23.61, 68.68) 61.38 (37.25, 101.17) F: 1.0 P: 0.37
Raised calprotectin (%)c 41.7 (21.2, 62.2) 44.0 (23.8, 64.2) 52.2 (30.9, 73.4) OR: 1.24 P: 0.47
Abbreviations: ANOVA, analysis of variance; BMI, body mass index; CI, confidence interval; EndoCAb, endotoxin core antibody; OR, odds ratio, PMU,
percentage median unit. aANOVA test conducted on log transformed variables to satisfy assumptions of normality. Individuals in the lean group coded 1,
obese 2 and diabetic 3. Logistic regression conducted on the categorical calprotectin outcome. bEndotoxin-core antibodies (EndoCAb) were determined in
‘median units’ relative to a standard of healthy UK blood donors and normalised to the lean population where the mean is shown as 100 PMU (‘percent
median units’). cProportion of individuals with calprotectin levels above the normal threshold of 50mg kg 1.
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fat mass and endotoxin or anti-endotoxin IgG antibodies (data not
shown).
An adjusted regression analysis was conducted to investigate
the independent effect of obesity and diabetes on endotoxin and
inﬂammatory markers. The initial model included obesity only
with the subsequent models ﬁtting both obesity and diabetes
variables to assess any independent association with the out-
comes of interest (Table 3). For this analysis, only individuals with
fasting plasma glucose 47.0mmol l 1 were deﬁned as having
type 2 diabetes rather than including all individuals recruited from
the diabetic clinic. Endotoxin was associated only with diabetes,
whereas anti-endotoxin IgM antibodies and IL-6 were associated
independently with both obesity and diabetes. Fitting potential
confounding variables to the models (age, education, assets
owned and water or waste management) did not affect the results
(data not shown).
DISCUSSION
This ‘proof-of-principal’ study reveals some of the strongest
human evidence to date in support of the theory that gut
microbiota-derived bacterial products may drive a chronic low-
grade inﬂammation that predisposes to insulin resistance and
diabetes.
The potential role of the gut microbiota in the development of
obesity and associated metabolic complications is receiving
increasing attention. Animal studies have allowed for experiments
into the causal nature of this association. Germ-free mice are
protected against the development of ‘Western’ diet-induced
insulin resistance12 and transplantation of gut microbiota from
obese mice into germ-free animals results in greater adiposity
than transplant from lean donors.13 Studies in humans have also
suggested the presence of an obesity-predisposing gut
microbiome that can be amended by weight loss.25,26
In addition to a potential role in increased energy harvest, the
gut microbiota are suggested as an important source of obesity-
associated inﬂammation; a recognised driver of the pathogenesis
of metabolic disease such as type 2 diabetes.
Substantial epidemiological evidence supports the role of
inﬂammation in the pathogenesis of obesity and type 2
diabetes.5,6 The mechanisms are not fully understood but one
potential pathway is the inactivation of the insulin receptor due to
the binding of inﬂammatory factors (such as TNF-a) with insulin
receptor substrate.27 Macrophage inﬁltration of adipose tissue is
an important source of inﬂammation associated with obesity,
however, the swift resolution of inﬂammation and insulin
resistance following bariatric surgery in patients with type 2
diabetes requires an explanation and has suggested the existence
of pathways operating independently of weight loss,28,29 with
bacterial endotoxin emerging as a putative candidate. Endotoxin
is a potent stimulator of inﬂammation through CD14-induced
secretion of cytokines (for example, TNF-a, IL-1 and IL-6) by
macrophages.18 In mouse models, antibiotic-induced changes to
the gut microbiota have been shown to result in reduced
endotoxemia and improvements in metabolic disorders
including adipose tissue inﬂammation and macrophage
inﬁltration.30 In human studies, ex-vivo treatment of adipose
tissue with LPS causes an increase in the secretion of inﬂammatory
markers TNF-a and IL-6.31
Certain constituents of the diet also are known to stimulate the
release of pro-inﬂammatory cytokines; meals with a high-fat
content have been implicated as a trigger of post-prandial
inﬂammation through the activation of NF-kB.32,33 However, the
mechanisms of high-fat-induced low-grade inﬂammation are
unclear and may also suggest a link with the gut microbiota.34
For example, single-meal intervention studies have indicated that
certain food types (fat and glucose) lead to raised endotoxin as
part of post-prandial inﬂammation.35–37 In mouse models, a high-
fat diet has been shown to initiate ME and CD14 knock-out mice
are resistant to these effects.9 LPS has been shown to be
transported by chylomicrons further suggesting a mechanism
through which the fat composition of the diet may impact on
endotoxin levels.34 Endotoxin concentration is also determined by
the integrity of the gut barrier, which may also be affected by the
diet; prebiotic-treated mice have improved intestinal integrity and
correspondingly lower plasma LPS.30
Endotoxin levels observed in the current study were similar
to those in a cross-sectional study of patients attending hospital
in Saudi Arabia, where mean levels for non-diabetics
were 4.2 EUml 1 and for diabetics treated with insulin were
Table 3. Association between endotoxin and inflammatory markers with obesity and diabetes separately
Variable Condition Mean difference (95% CI)a P-value
Log endotoxin (EUml 1) Obesity 0.14 ( 0.08, 0.37) 0.21
Obesity adj for diabetes 0.001 ( 0.24, 0.24) 0.99
Diabetes adj for obesity 0.43 (0.16, 0.70) 0.002
Log EndoCAb-IgG (PMU)b Obesity 0.14 ( 0.18, 0.45) 0.39
Obesity adj for diabetes 0.19 ( 0.16, 0.54) 0.29
Diabetes adj for obesity  0.07 ( 0.46, 0.32) 0.73
Log EndoCAb-IgM (PMU)b Obesity  0.88 ( 1.21,  0.55) o0.001
Obesity adj for diabetes  0.69 ( 1.04,  0.34) o0.001
Diabetes adj for obesity  0.53 ( 0.92,  0.14) 0.01
Log total IgM (mgdl 1) Obesity 0.06 ( 0.44, 0.56) 0.81
Obesity adj for diabetes 0.17 ( 0.39, 0.74) 0.55
Diabetes adj for obesity  0.27 ( 0.89, 0.35) 0.38
Log faecal calprotectin (mg kg 1) Obesity 0.22 ( 0.38, 0.83) 0.46
Obesity adj for diabetes 0.20 ( 0.47, 0.86) 0.56
Diabetes adj for obesity 0.29 ( 0.46, 1.03) 0.45
Log IL-6 (pgml 1) Obesity 0.38 (0.21, 0.56) o0.001
Obesity adj for diabetes 0.31 (0.12, 0.51) 0.002
Diabetes adj for obesity 0.21 ( 0.01, 0.43) 0.06
Abbreviations: adj, adjusted; CI, confidence interval; EndoCAb, endotoxin core antibodies; PMU, percentage median unit. aEffect estimates from linear
regression analysis. Obesity model includes obesity (coded 1,0) only. ‘Obesity adj for diabetes’ and ‘Diabetes adj for obesity’ includes both obesity and
diabetes variables (coded 1,0) fitted to the same model to assess independent association. Mean difference refers to difference in independent variable for
obese compared with lean individuals or for diabetic (defined as fasting plasma glucose 47.0mmol l 1) compared with non-diabetic individuals bEndoCAb
were determined in ‘median units’ relative to a standard of healthy UK blood donors and normalised to the lean population where the mean is shown as
100 PMU.
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9.2 EUml 1.16 A separate study of diabetic subjects and BMI-
matched controls reported a 76% higher endotoxin concentration
among the diabetics.31 In the present study, both EndoCAb-IgG
and -IgM antibodies were measured in addition to circulating
endotoxin. EndoCAb-IgG levels were similar for the three groups.
In contrast, EndoCAb-IgM levels were highly signiﬁcantly lower in
the obese and obese diabetic groups compared with their lean
counterparts (F¼ 21.7, Po0.0001). There was virtually no overlap
in EndoCAb-IgM levels between the three groups. Total IgM
antibodies remained similar across the groups demonstrating an
EndoCAb-speciﬁc effect. Note that the strong correlation between
repeat measures of EndoCAb IgM validates our choice of this as a
more robust marker of chronic exposure than LPS levels, which
may vary with day-to-day changes in dietary patterns and showed
a very poor intra-subject reproducibility. The paradoxical
reduction in EndoCAb IgM levels in the obese and obese
diabetics were unexpected and are challenging to explain. We
hypothesise that it could be caused by degradation of IgM–LPS
complex that is constantly neutralising a persistent endotoxin
leakage from the gut. This might also help to explain why there is
no such trend in EndoCAb-IgG levels. In settings with high
background antibody levels, repeated exposure to endotoxin may
not necessarily stimulate a new IgG-mediated immune response if
there is sufﬁcient antibody to neutralise incoming LPS. Depletion
of circulating EndoCAb levels as the LPS–antibody complex is
cleared may erode IgM antibodies much faster than IgG
antibodies, as only 20% of IgG is in circulation and will be
supplemented from the 80% extravascular pool of IgG.38 The
relative kinetics of IgM and IgG EndoCAb in this context is
currently unknown and should be explored in future studies.
Alternatively, chronic exposure among the obese and diabetic
obese patients may have induced antibody class switching
or even immune tolerance. Although there was no evidence for
increased EndoCAb-IgG, we did not measure IgG isotypes in this
study. It remains possible that the chronically exposed individuals
produce an IgG of higher afﬁnity rather than simply larger
quantities.
Faecal calprotectin has been validated as a marker of gut
inﬂammation against endoscopic and histologic grading of
disease, and excretion of indium-111-labelled neutrophils, in
ulcerative colitis patients.20 The lack of any trend in this study
might reﬂect the fact that it is a marker for more severe gut
inﬂammation than is required to elicit endotoxin translocation.
Alternatively, lipid-chaperoned translocation of LPS (and/or other
bacterial debris) might occur even in the absence of gut damage
as suggested by studies of post-prandial inﬂammation in response
to high-fat meals.31–36
There are a number of strengths of the current study. The three
groups are well matched for age and for urban living and were
selected to ensure there is a large difference between the lean
and obese phenotypes in terms of their adiposity. Standard
techniques were used to assess the study outcomes with validated
commercial ELISA kits for the assessment of IL-6, faecal
calprotectin and total IgM and the end point chromogenic
Limulus Amebocyte Lysate assay for the assessment of endotoxin.
The assessment of endotoxin antibodies was conducted using an
ELISA, originally developed for screening blood donors but which
has also been used in other settings including screening blood
donors for clinically useful antibodies for passive immunoprophy-
laxis39 and demonstrated excellent sensitivity for assessing
chronic exposure with a repeat measures correlation of 0.82 in
samples collected a fortnight apart.
The major limitation of the current study is that so far we only
have cross-sectional data and, hence, cannot infer causality.
A further limitation is the lack of information on dietary intake.
Future diet manipulation studies will be required to aid
our understanding of the link between diet, obesity and the gut
microbiota impacts on metabolic disease.
In conclusion, we have shown that in urban Gambian women
type 2 diabetes is associated with convincing evidence of ME,
presumably due to translocation of bacterial products originating
in the gut. The paradoxical reduction in anti-endotoxin IgM
antibodies tentatively suggests that constant immunosurveillance
may be depleting the available neutralising antibody. The
markedly lower levels in diabetics could indicate either a greater
exposure (driven by an altered microbiota and/or a more leaky gut
and/or altered diet) or an impaired ability to sustain neutralising
defences. Whether this is a particular attribute of diabetes in a
low-income setting, where a persistent ‘environmental entero-
pathy’ has long been recognised as a contributor to growth
faltering in children,40 remains to be tested. If these ﬁndings are
replicated in other studies, and a causal pathway emerges
between diet composition, the composition and behaviour
of the microbiota, damage to gut integrity and translocation of
inﬂammatory agonists that ultimately impair insulin signalling,
then this would open new avenues for intervention.
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